Supplementary Material – Real-World Cost-Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High FN Risk

Supplemental Figure 1. Algorithm for assessing FN risk and the need for primary prophylactic G-CSF

Supplemental Figure 2. PSA Cost-Effectiveness Acceptability Curves, by Outcome and Risk Group

Supplemental Figure 3. OWSA Tornado Diagrams for Incremental Cost-effectiveness Ratios, By Outcome